Skip to main content
PMC home page
Elsevier - PMC COVID-19 Collection logoLink to Elsevier - PMC COVID-19 Collection
. 2003 Mar 19;115:S3–S15. doi: 10.1016/0022-510X(93)90203-B

The pathogenesis of multiple sclerosis

Additional considerations

Charles M Poser 1,1
PMCID: PMC7130122  PMID: 7688036

Abstract

Multiple sclerosis (MS) is acquired as a systemic “trait” by individuals who are genetically susceptible. This condition does not involve the central nervous system (CNS) and is characterized by a state of hyperactive immunocompetent responsiveness. It develops as the result of an antigenic challenge by a viral protein, either from a viral infection or a vaccination. In order for MS to become a disease affecting the CNS, it is necessary for the blood-brain barrier's (BBB) impermeability to be altered. This is now a fully recognized fact. As a result of this change, the MS lesion, which consists of edema and inflammation occurs. It may but need not lead to demyelination. Several mechanisms can cause this increased permeability of the BBB. The role of the immune system, and in particular of T lymphocytes in initiating and continuing the process of lesion formation remains extremely controversial. In fact, there are unanswered questions regarding the actual target of MS: is it the myelin sheath itself or its forming cell, the oligodendrocyte, or is it the BBB itself leading to bystander demyelination? The role of mild, concussional trauma to the CNS in producing the alteration of the BBB and therefore acting as a trigger or facilitator in the development or enlargement of MS lesions in the CNS, is based on considerable clinical, neuropathological and experimental evidence. Along with another viral infection, it must be one of the commonest causes of progression of MS, and quite often leads to the onset of the clinical manifestations of an hitherto asymptomatic condition.

Keywords: Multiple sclerosis, Pathogenesis, Blood-brain barrier, Trauma, Disease progression, Multiple sclerosis trait

References

  1. Abou-Dia M. Organophosphorous ester-induced delayed neurotoxicity. Annu. Rev. Pharmacol. Toxicol. 1981;21:511–548. doi: 10.1146/annurev.pa.21.040181.002455. [DOI] [PubMed] [Google Scholar]
  2. Adams C., Poston R., Buk S. Inflammatory vasculitis in MS. J. Neurol. Sci. 1985;69:269–283. doi: 10.1016/0022-510x(85)90139-x. [DOI] [PubMed] [Google Scholar]
  3. Allen I. Aetiological implications. In: Matthews W., editor. McAlpine's Multiple Sclerosis. 2nd edn. Churchill Livingstone; Edinburgh: 1991. p. 375. [Google Scholar]
  4. Alvord E. Experimental allergic encephalomyelitis and experimental allergic neuritis. In: Vinken P.J., Bruyn G.W., Koetsier J., editors. vol. 3. Elsevier; Amsterdam: 1985. pp. 429–466. (Handbook of Neurology: Demyelinating diseases). [Google Scholar]
  5. Arnon R., Crisp E., Kelley R., Ellison G., Meyers L., Tourtellotte W. Anti-ganglioside antibodies in MS. J. Neurol. Sci. 1980;46:179–186. doi: 10.1016/0022-510x(80)90076-3. [DOI] [PubMed] [Google Scholar]
  6. Atkins G., Daly E., Sheahan B., Higgins D., Sharp P. MS and molecular mimicry. Neuropathol. Appl. Neurobiol. 1990;16:179. doi: 10.1111/j.1365-2990.1990.tb00946.x. [DOI] [PubMed] [Google Scholar]
  7. Axthelm M., Krakowka S. Canine distemper virus: the early blood-brain barrier lesion. Acta Neuropathol. 1987;75:27–33. doi: 10.1007/BF00686789. [DOI] [PubMed] [Google Scholar]
  8. Bakay L., Lee J., Lee G. Experimental cerebral concussion. Part I: An electron microscopic study. J. Neurosurg. 1977;47:346–352. doi: 10.3171/jns.1977.47.4.0525. [DOI] [PubMed] [Google Scholar]
  9. Barnes D., Munro P., Youl B., Prineas J., McDonald W. The longstanding MS lesions. Brain. 1991;114:1271–1280. doi: 10.1093/brain/114.3.1271. [DOI] [PubMed] [Google Scholar]
  10. Baum K., Girke W., Braeu T. Zur Bedeutung der magnetischen Resonanz-Tomographie bei Encephalomyelitis disseminata. Nervenarzt. 1985;56:666–672. [PubMed] [Google Scholar]
  11. Binder L. Persisting symptoms after mild head injury: A review of the postconcussive syndrome. J. Clin. Exp. Neuropsychol. 1986;8:323–346. doi: 10.1080/01688638608401325. [DOI] [PubMed] [Google Scholar]
  12. Brain W., Wilkinson M. The association of cervical spondylosis and disseminated sclerosis. Brain. 1957;80:456–478. doi: 10.1093/brain/80.4.456. [DOI] [PubMed] [Google Scholar]
  13. Brody J., Sever J., Henson T. Virus antibody titers in MS patients, siblings and controls. J.A.M.A. 1971;216:1441–1446. [PubMed] [Google Scholar]
  14. Broman T. Munksgaard; Copenhagen: 1949. The Permeability of the Cerebrospinal Vessels in Normal and Pathological Conditions; p. 66. [Google Scholar]
  15. Chou Y., Bourdette D., Offner H. Frequency of T cells specific for myelin basic protein and myelin proteolipid protein in blood and cerebrospinal fluid in MS. J. Neuroimmunol. 1992;38:105–115. doi: 10.1016/0165-5728(92)90095-3. [DOI] [PubMed] [Google Scholar]
  16. Clark G., Bogdanove L. The induction of the lesions of allergic meningoencephalomyelitis in a predetermined location. J. Neuropathol. Exp. Neurol. 1955;14:433–437. [PubMed] [Google Scholar]
  17. Compston D. Immunological aspects of MS. In: Matthews W., editor. McAlpine's Multiple Sclerosis. 2nd edn. Churchill Livingstone; Edinburgh: 1991. p. 328. [Google Scholar]
  18. Compston D. Limiting and repairing the damage in MS. J. Neurol. Neurosurg. Psychiat. 1991;54:945–948. doi: 10.1136/jnnp.54.11.945. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Coyle P., Hirsch R., O'Donnell P. Cerebrospinal fluid lymphocyte population and immune complexes in active MS. Lancet. 1980;2:229–232. doi: 10.1016/s0140-6736(80)90121-x. [DOI] [PubMed] [Google Scholar]
  20. Davison A. The relevance of experimental allergic encephalomyelitis to MS. J. R. Soc. Med. 1992;85:425–426. [Google Scholar]
  21. Domer F., Liu Y., Chandran K., Krieger K. Effect of hyperextension-hyperflexion (whiplash) on the function of the blood-brain barrier of Rhesus monkeys. Exp. Neurol. 1979;63:304–310. doi: 10.1016/0014-4886(79)90126-2. [DOI] [PubMed] [Google Scholar]
  22. Dousset V., Grossman R., Ramer K. Experimental allergic encephalomyelitis and MS: lesion characterization with magnetization transfer imaging. Radiology. 1992;182:483–491. doi: 10.1148/radiology.182.2.1732968. [DOI] [PubMed] [Google Scholar]
  23. Duquette P. Familial subclinical MS. Neurology. 1991;41:159. doi: 10.1212/wnl.41.1.159-b. [DOI] [PubMed] [Google Scholar]
  24. Escobar A., Aruffo C. Chronic thinner intoxication: clinicopathologic report of a human case. J. Neurol. Neurosurg. Psychiat. 1980;43:986–994. doi: 10.1136/jnnp.43.11.986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Estes M., Rudick R., Barnett G., Ransohoff R. Stereotactic biopsy of an active MS lesion. Arch. Neurol. 1990;47:1299–1303. doi: 10.1001/archneur.1990.00530120043008. [DOI] [PubMed] [Google Scholar]
  26. Filley C., Heaton R., Rosenberg N. White matter dementia in chronic toluene abuse. Neurology. 1990;40:532–534. doi: 10.1212/wnl.40.3_part_1.532. [DOI] [PubMed] [Google Scholar]
  27. Fredrikson S., Michelsberg J., Hillert J. Conjugal MS: Immunogenetic characterization and analysis of T- and B-cell reactivity to myelin proteins. Neurology. 1992;42:577–582. doi: 10.1212/wnl.42.3.577. [DOI] [PubMed] [Google Scholar]
  28. Fujinami R., Oldstone M., Wroblewska Z. Vol. 80. 1983. Molecular mimicry in virus infections; pp. 2346–2350. (Proc. Natl. Acad. Sci. USA). [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Gay D., Esiri M. Blood-brain barrier damage in acute MS plaques. Brain. 1991;114:557–572. doi: 10.1093/brain/114.1.557. [DOI] [PubMed] [Google Scholar]
  30. Gonsette R., Andre-Balisaux G., Delmotte P. La perméabilité des vaisseaux cérébraux. VI. Démyélinisation expérimentale provoquée par des substances agissant sur la barrière hémato-encéphalique. Acta Neurol. Belg. 1966;66:247–262. [PubMed] [Google Scholar]
  31. Goodman J., Bingham W., Hunt W. Ultrastructural blood-brain barrier alteration and edema formation in acute spinal cord trauma. J. Neurosurg. 1976;44:418–424. doi: 10.3171/jns.1976.44.4.0418. [DOI] [PubMed] [Google Scholar]
  32. Gyorkey F., Melnick J., Gyorkey P. Human immunodeficiency virus in brain biopsies of patients with AIDS and progressive encephalopathy. J. Infect. Dis. 1987;155:870–876. doi: 10.1093/infdis/155.5.870. [DOI] [PubMed] [Google Scholar]
  33. Haile R., Karavodin L., Visscher B., Detels R. Similar levels of immune complexes in cases of MS and their unaffected relatives. J. Neuroimmunol. 1981;1:183–190. doi: 10.1016/0165-5728(81)90042-4. [DOI] [PubMed] [Google Scholar]
  34. Hardman J. The pathology of traumatic brain injuries. Adv. Pathol. 1979;22:15–50. [PubMed] [Google Scholar]
  35. Hickey W. Migration of hematogenous cells through the blood-brain barrier and the initiation of CNS inflammation. Brain Pathol. 1991;1:97–105. doi: 10.1111/j.1750-3639.1991.tb00646.x. [DOI] [PubMed] [Google Scholar]
  36. Hsu C., Hogan E., Gadsden R., Spicer K., Shi M., Cox R. Vascular permeability in experimental spinal cord injury. J. Neurol. Sci. 1985;70:275–282. doi: 10.1016/0022-510x(85)90169-8. [DOI] [PubMed] [Google Scholar]
  37. Hughes R. Pathogenesis of MS. J. R. Soc. Med. 1992;85:373–375. [PMC free article] [PubMed] [Google Scholar]
  38. Isacson P., Stone A. Allergic reactions associated with viral vaccines. Progr. Med. Virol. 1971;13:239–270. [PubMed] [Google Scholar]
  39. Jahnke U., Fischer E., Alvord E. Sequence homology between certain viral proteins and proteins related to encephalomyelitis and neuritis. Science. 1985;229:282–284. doi: 10.1126/science.2409602. [DOI] [PubMed] [Google Scholar]
  40. Jenkins A., Teasdale G., Howley M., Macpherson P., Rowan J. Brain lesions detected by MRI in mild and severe head injuries. Lancet. 1986;2:445–446. doi: 10.1016/s0140-6736(86)92145-8. [DOI] [PubMed] [Google Scholar]
  41. Jingzu Z., Medaer R., Hashim G., Chin Y., van den Berg-Loonen E., Raus J. Myelin basic protein specific T lymphocytes in MS and controls: precursor frequency, fine specificty, and cytotoxicity. Ann. Neurol. 1992;32:330–338. doi: 10.1002/ana.410320305. [DOI] [PubMed] [Google Scholar]
  42. Johnson D., Hafler D., Fallis D. Cell-mediated immunity to myelin-associated glycoprotein, proteolipid protein, and myelin basic protein in MS. J. Neuroimmunol. 1986;13:99–108. doi: 10.1016/0165-5728(86)90053-6. [DOI] [PubMed] [Google Scholar]
  43. Johnson M., Li D., Bryant D. Magnetic resonance imaging: serial observations in MS. A.J.N.R. 1984;5:495–499. [PMC free article] [PubMed] [Google Scholar]
  44. Kapadia S. Ultrastructural alterations in blood vessels of the white matter after experimental cord trauma. J. Neurosurg. 1984;61:539–544. doi: 10.3171/jns.1984.61.3.0539. [DOI] [PubMed] [Google Scholar]
  45. Kelly J., Nichols J., Filley C., Lillehei K., Rubinstein D., Kleinschmidt-DeMasters B. Concussion in sports: guidelines for the prevention of catastrophic outcome. J.A.M.A. 1991;266:2867–2869. doi: 10.1001/jama.266.20.2867. [DOI] [PubMed] [Google Scholar]
  46. Kinnunen E., Valle M., Piiranen L. Viral antibodies in MS: an nationwide co-twin study. Arch. Neurol. 1990;47:743–746. doi: 10.1001/archneur.1990.00530070031008. [DOI] [PubMed] [Google Scholar]
  47. Lassmann H., Zimprich F., Rossler K., Vass K. Inflammation in the nervous system: basic mechanisms and immunological concepts. Rev. Neurol. 1991;147:763–781. [PubMed] [Google Scholar]
  48. Levin H., Amparo E., Eisenberg H. Magnetic resonance imaging and computerized tomography in relation to neurobehavioral sequelae of mild and moderate head injuries. J. Neurosurg. 1987;66:706–713. doi: 10.3171/jns.1987.66.5.0706. [DOI] [PubMed] [Google Scholar]
  49. Levin H., Williams D., Crofford M. Relationship of depth of brain lesions to consciousness and outcome of closed head injury. J. Neurosurg. 1988;69:861–866. doi: 10.3171/jns.1988.69.6.0861. [DOI] [PubMed] [Google Scholar]
  50. Levin H., Williams D., Eisenberg H., High W., Guinto F. Serial MRI and neurobehavioural findings after mild to moderate head injury. J. Neurol. Neurosurg. Psychiat. 1992;55:255–262. doi: 10.1136/jnnp.55.4.255. [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Levine S., Hoenig E. Induced localization of allergic adrenalitis and encephalomyelitis at sites of thermal injury. J. Immunol. 1968;100:1310–1318. [PubMed] [Google Scholar]
  52. Lisak R. Immunological abnormalities. In: McDonald W., Silberberg D., editors. Multiple Sclerosis. Butterworths; London: 1986. p. 74. [Google Scholar]
  53. Lumsden C. The clinical immunology of MS. In: McAlpine D., Lumsden C., Acheson E., editors. Multiple Sclerosis: a reappraisal. 2nd edn. Williams and Wilkins; Baltimore, MD: 1972. pp. 518–519. [Google Scholar]
  54. Lynch S., Rose J. Reply to “Familial subclinical MS” by Duquette. P. Neurology. 1991;41:159. doi: 10.1212/wnl.41.1.159-b. [DOI] [PubMed] [Google Scholar]
  55. Martino G., Olsson T., Fredrikson S. Cells producing antibodies specific for myelin basic protein region 70–89 are predominant in cerebrospinal fluid from patients with MS. Eur. J. Immunol. 1991;21:2971–2976. doi: 10.1002/eji.1830211211. [DOI] [PubMed] [Google Scholar]
  56. Matthews W. Pathophysiology. In: Matthews W., editor. McAlpine's Multiple Sclerosis. 2nd edn. Churchill Livingstone; Edinburgh: 1991. p. 243. [Google Scholar]
  57. Maxwell W., Irvine A., Hume Adams J., Graham D., Gennarelli T. Response of cerebral microvasculature to brain injury. J. Pathol. 1988;155:327–335. doi: 10.1002/path.1711550408. [DOI] [PubMed] [Google Scholar]
  58. Murray R., Brown B., Brian D., Cabirac G. Detection of Corona virus RNA and antigen in MS brain. Ann. Neurol. 1992;31:525–533. doi: 10.1002/ana.410310511. [DOI] [PMC free article] [PubMed] [Google Scholar]
  59. Nevin N. Neuropathologic change in the white matter following head injury. J. Neuropathol. Exp. Neurol. 1967;26:77–84. doi: 10.1097/00005072-196701000-00006. [DOI] [PubMed] [Google Scholar]
  60. Newcombe J., Hawkins C., Henderson C. Histopathology of MS lesions detected by MRI in unfixed postmortem central nervous system. Brain. 1991;114:1013–1023. doi: 10.1093/brain/114.2.1013. [DOI] [PubMed] [Google Scholar]
  61. Naqvi S.H., Mahdi, Haider S. Neurochemical effects of phosphamidon on lipid fraction and lipid peroxidation in the rat central nervous system. Indian J. Med. Res. 1988;88:85–90. [PubMed] [Google Scholar]
  62. Noble G., Kaye H., Kendal A., Dowdle W. Age-related heterologous antibody responses to influenza virus vaccination. J. Infect. Dis. 1977;136:S686–S692. doi: 10.1093/infdis/136.supplement_3.s686. Suppl. [DOI] [PubMed] [Google Scholar]
  63. Oger J., Kastrukoff L., Li D. MS: in relapsing patients, immune functions vary with disease activity as assessed by MRI. Neurology. 1988;38:1739–1744. doi: 10.1212/wnl.38.11.1739. [DOI] [PubMed] [Google Scholar]
  64. Olsson T., Zhi W., Hojeberg B. Autoreactive T lymphocytes in MS determined by antigen-induced secretion of interferon-gamma. J. Clin. Invest. 1990;86:981–985. doi: 10.1172/JCI114800. [DOI] [PMC free article] [PubMed] [Google Scholar]
  65. Ommaya A., Rockoff D., Baldwin M. Experimental concussion: a first report. J. Neurosurg. 1964;21:249–265. doi: 10.3171/jns.1964.21.4.0249. [DOI] [PubMed] [Google Scholar]
  66. Oppenheimer D. Microscopic lesions in the brain following head injury. J. Neurol. Neurosurg. Psychiat. 1968;31:299–306. doi: 10.1136/jnnp.31.4.299. [DOI] [PMC free article] [PubMed] [Google Scholar]
  67. Oppenheimer D. The cervical cord in MS. Neuropathol. Appl. Neurobiol. 1978;4:151–162. doi: 10.1111/j.1365-2990.1978.tb00555.x. [DOI] [PubMed] [Google Scholar]
  68. Panelius M., Salmi A., Halonen P. Virus antibodies in serum specimens from patients with MS, from siblings, and matched controls. A final reportActa Neurol. Scand. 1973;49:85–107. doi: 10.1111/j.1600-0404.1973.tb01281.x. [DOI] [PubMed] [Google Scholar]
  69. Poser C. Disseminated vasculomyelinopathy. Acta Neurol. Scand. 1969;45(Suppl. 37):1–44. [Google Scholar]
  70. Poser C. Trauma, stress and MS. Bull. Am. Acad. Psychiat. Law. 1979;7:208–219. [PubMed] [Google Scholar]
  71. Poser C. The course of MS. Arch. Neurol. 1985;42:1035. doi: 10.1001/archneur.1985.04060100013004. [DOI] [PubMed] [Google Scholar]
  72. Poser C. The pathogenesis of MS: a critical reappraisal. Acta Neuropathol. 1986;71:1–10. doi: 10.1007/BF00687954. [DOI] [PubMed] [Google Scholar]
  73. Poser C. Trauma and multiple sclerosis. J. Neurol. 1987;254:155–159. doi: 10.1007/BF00314135. [DOI] [PubMed] [Google Scholar]
  74. Poser C. Multiple sclerosis. Observations and reflections - a personal memoirJ. Neurol. Sci. 1992;107:127–140. doi: 10.1016/0022-510x(92)90280-x. [DOI] [PubMed] [Google Scholar]
  75. Poser C. Neurological complications of infections and vaccinations. Saudi Med. J. 1992;13:379–386. [Google Scholar]
  76. Poser C., Kleefield J., O'Reilly G., Jolesz F. Neuro-imaging and the lesion of MS. A.J.N.R. 1987;8:549–552. [PMC free article] [PubMed] [Google Scholar]
  77. Poser C., Benedikz J., Hibberd P. The epidemiology of MS: the Iceland model. Onset-adjusted prevalence rate and other methodological considerationsJ. Neurol. Sci. 1992;111:143–152. doi: 10.1016/0022-510x(92)90062-p. [DOI] [PubMed] [Google Scholar]
  78. Reik L. Disseminated vasculomyelinopathy. Ann. Neurol. 1980;7:291–296. doi: 10.1002/ana.410070402. [DOI] [PubMed] [Google Scholar]
  79. Raine C. MS: a pivotal role for the T cell in lesion development. Neuropathol. Appl. Neurobiol. 1991;17:265–274. doi: 10.1111/j.1365-2990.1991.tb00724.x. [DOI] [PubMed] [Google Scholar]
  80. Riechert T., Hassler R., Mundinger F. Pathologic-anatomical findings and cerebral localization in stereotactic treatment of extrapyramidal motor disturbances in MS. Confin. Neurol. 1975;37:24–40. doi: 10.1159/000102709. [DOI] [PubMed] [Google Scholar]
  81. Rimel B., Giordani B., Barth J., Boll T., Jane J. Disability caused by minor head injury. Neurosurgery. 1981;9:221–228. [PubMed] [Google Scholar]
  82. Rosen J., Brown M., Hickey W., Rostami A. Early myelin lesions in experimental allergic neuritis. Muscle Nerve. 1990;13:629–636. doi: 10.1002/mus.880130712. [DOI] [PubMed] [Google Scholar]
  83. Rosenberg N., Kleinschmidt-DeMasters B., Davis K., Dreisbach J., Hormes J., Filley C. Toluene causes diffuse central nervous system white matter changes. Ann. Neurol. 1988;23:611–614. doi: 10.1002/ana.410230614. [DOI] [PubMed] [Google Scholar]
  84. Rudge P. Does a retrovirally encoded superantigen cause MS? J. Neurol. Neurosurg. Psychiat. 1991;54:853–855. doi: 10.1136/jnnp.54.10.853. [DOI] [PMC free article] [PubMed] [Google Scholar]
  85. Summers B., Greisen H., Appel M. Early events in canine distemper demyelinating encephalomyelitis. Acta Neuropathol. 1979;46:1–10. doi: 10.1007/BF00684797. [DOI] [PubMed] [Google Scholar]
  86. Sun J., Link H., Olsson T. T and B cell responses to myelin-oligodendrocyte glycoprotein in MS. J. Immunol. 1991;146:1490–1495. [PubMed] [Google Scholar]
  87. Thompson A., Miller D., Youl B. Serial gadolinium-enhanced MRI in relapsing/remitting MS of varying disease duration. Neurology. 1992;42:60–63. doi: 10.1212/wnl.42.1.60. [DOI] [PubMed] [Google Scholar]
  88. Toro G., Vergara I., Roman G. Neuroparalytic accidents of anti-rabies vaccination with suckling mouse brain vaccine. Arch. Neurol. 1977;34:694–700. doi: 10.1001/archneur.1977.00500230064011. [DOI] [PubMed] [Google Scholar]
  89. Tsukada N., Koh C., Yanagisawa N. A new model for MS: chronic experimental encephalomyelitis induced by immunization with cerebral endothelial cell membrane. Acta Neuropathol. 1987;73:259–266. doi: 10.1007/BF00686620. [DOI] [PubMed] [Google Scholar]
  90. Uchimura I., Shiraki H. A contribution to the classification and pathogenesis of demyelinating encephalomyelitis with special reference to the central nervous system lesions caused by preventive inoculation against rabies. J. Neuropathol. Exp. Neurol. 1957;16:139–203. doi: 10.1097/00005072-195704000-00001. [DOI] [PubMed] [Google Scholar]
  91. Uhlenbrock D., Herbe E., Seidel D. One-year MR imaging follow-up of patients with MS under cortisone therapy. Neuroradiology. 1989;31:3–7. doi: 10.1007/BF00342020. [DOI] [PubMed] [Google Scholar]
  92. Wadia R., Sadagopan C., Amin R., Sardesai H. Neurological manifestations of organophosphorous insecticide poisoning. J. Neurol. Neurosurg. Psychiat. 1974;37:841–847. doi: 10.1136/jnnp.37.7.841. [DOI] [PMC free article] [PubMed] [Google Scholar]
  93. Weintraub M. Trauma and MS: medico-legal implications. Dev. Med. Child Neurol. 1988;30:407–408. [PubMed] [Google Scholar]
  94. Wekerle H., Linington C., Lassmann H., Meyerman R. Cellular immune reactivity within the CNS. Trends Neurol. Sci. 1986;9:271–277. [Google Scholar]
  95. Wisniewski H., Bloom B. Primary demyelination as a nonspecific consequence of cell-mediated immune reaction. J. Exp. Med. 1975;141:346–359. doi: 10.1084/jem.141.2.346. [DOI] [PMC free article] [PubMed] [Google Scholar]
  96. Wolfgram F. What if MS isn't an immunological or viral disease? Neurochem. Res. 1979;4:1–14. doi: 10.1007/BF00963827. [DOI] [PubMed] [Google Scholar]
  97. Woyciechowska J., Dambrozia J., Leinikki P. Viral antibodies in twins with MS. Neurology. 1985;35:1176–1180. doi: 10.1212/wnl.35.8.1176. [DOI] [PubMed] [Google Scholar]
  98. Xu X., McFarlin D. Oligoclonal bands in CSF: twins with MS. Neurology. 1984;34:769–774. doi: 10.1212/wnl.34.6.769. [DOI] [PubMed] [Google Scholar]
  99. Zamvil S., Steinman L. The T lymphocyte in experimental allergic encephalomyelitis. Annu. Rev. Immunol. 1990;89:579–621. doi: 10.1146/annurev.iy.08.040190.003051. [DOI] [PubMed] [Google Scholar]

Articles from Journal of the Neurological Sciences are provided here courtesy of Elsevier

RESOURCES